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The incidence of inflammatory bowel diseases (IBD), including Crohn’s disease (CD), is
increasing worldwide, especially in young children and adolescents. Although hospitalized
patients are usually provided with enteral or parenteral support, continuing care typically
requires a trial-and-error approach to suppressing symptoms and maintaining disease
remission. Current nutritional advice does not differ from general population guidelines.
International collaborative studies have revealed 163 distinct genetic loci affecting
susceptibility to IBD, in some of which host–microbe interactions can be seen to play
an important role. The nature of these loci enables a rationale for predicting nutritional
requirements that may not be evident through standard therapeutic approaches. Certain
recognized nutrients, such as vitamin D and long-chain omega-3 polyunsaturated fatty
acids, may be required at higher than anticipated levels. Various phytochemicals, not
usually considered in the same class as classic nutrients, could play an important role.
Prebiotics and probiotics may also be beneficial. Genomic approaches enable proof of
principle of nutrient optimization rather than waiting for disease symptoms to appear
and/or progress. We suggest a paradigm shift in diagnostic tools and nutritional therapy
for CD, involving a systems biology approach for implementation.
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introduction
Inflammatory bowel diseases (IBD) cover a spectrum of gastrointestinal disorders, including both 
Crohn’s disease (CD) and ulcerative colitis (UC), differentiated by their location and behavior. While 
these diseases were seen as rare in the early twentieth century, they have become increasingly com-
mon, causing gut inflammation, ulceration, and other symptoms, in up to 1 in 250 people worldwide. 
For example, they had not been previously described among Bedouin Arabs in Southern Israel, but 
numbers are increasing now, almost certainly because of their increasingly urbanized lifestyle (1). 
A recent commentary described IBD in Asia as the “emergence of a Western disease” (2). While 
observed previously in Australasia, these diseases are becoming more common in young children 
and adolescents (3).
There are a number of accepted treatments for CD, aimed not only to reduce the inflammation but 
also to improve the long-term prognosis (4). The most desirable end point, achieved in only a rela-
tively low proportion of cases at present, is long-term remission. One of the two approaches is used 
for CD treatment. “Step-up” starts with milder drugs first, while “top-down” gives people stronger 
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drugs earlier in the treatment process. Anti-inflammatory drugs 
are often the first step in the treatment. These include oral 
5-aminosalicylates, such as sulfasalazine and mesalamine, or 
corticosteroids. However, all of these lead to undesirable side 
effects. Immune system suppressors also reduce inflammation by 
targeting the immune system. These drugs include azathioprine 
(Imuran), mercaptopurine (Purinethol), infliximab (Remicade), 
adalimumab (Humira), and certolizumab pegol (Cimzia). The 
latter three drugs are inhibitors of the immune system protein 
tumor necrosis factor-alpha (TNF-α). It is important to realize, 
however, that the inflammatory response is a necessary part of 
response to an infection or injury, and long-term suppression of 
this may be disadvantageous.
Not only is CD itself debilitating, it also carries with it an 
increased risk of colorectal cancer (CRC) (5). The nature of 
this cancer is fundamentally different from the classic disease, 
which arises from an adenomatous polyp (6). The type of CRC 
that develops from either form of IBD is almost inevitably lethal. 
However, like sporadic CRC, it arises through genomic instability.
Genomic instability refers to the accumulation of mutations 
during the life cycle of cells (7–9). These mutations can involve 
changes at the level of nucleotide base pairs, chromosome rear-
rangements, or aneuploidy. Genomic instability can initiate 
cancer, augment cancer progression, and influence the overall 
prognosis of the affected patient. It arises from many different 
pathways, including telomere damage, centrosome amplification, 
epigenetic modifications, and DNA damage from endogenous 
and exogenous sources. Protection against genomic instability, 
or at least reduction of the probability, is an important function 
of certain nutrients and phytochemicals (7).
Although nutrition is an important consideration in hos-
pitalized patients, non-hospitalized patients are not currently 
being given nutritional guidelines outside those for the general 
population. We explore the possibility that thinking outside 
the current square in terms of nutrition might have significant 
beneficial effects beyond protection from malnutrition. That is, 
we suggest that nutrition could move from being an adjunct to 
therapy, to the point where it becomes primary therapy in its own 
right, integrated with currently accepted approaches (10). There 
is reason to suggest that this could have significant benefits in 
terms of delaying IBD progression and reducing the possibility 
of CRC formation. Such information would ideally be tailored 
according to individual patient genetics, and validated using 
systems biology approaches, as detailed in the following sections.
Diet in Non-Hospitalized CD Patients
Either prior to hospitalization or following discharge from 
hospital, dietary selection is determined by something of a 
random process (11). While the diet may be based on previous 
recollections of foods which affected symptoms, either in a 
positive or negative sense, it is often guided by advice from oth-
ers with the disease. It has been clear for some time that certain 
foods may have adverse effects in most subjects, exacerbating 
disease symptoms by increasing inflammation and/or produc-
ing flatulence. In some groups, there has been endorsement of 
a “low FODMAP” diet, as this appears to reduce some of the 
symptoms in CD and other functional gastrointestinal disor-
ders, especially irritable bowel syndrome (12, 13). FODMAP 
refers to the combination of saccharides and polyols and is 
an acronym of “Fermentable Oligo-, Di-, mono and polyols.” 
Against the recommendation for a low-FODMAP diet, there 
is a concern that such a structured dietary regime will have 
adverse effects in reducing dietary diversity. Of particular 
concern is the recognition that this same group of excluded 
nutrients plays a major role in modulating the composition of 
the gut microbiome (14).
It has been recognized that there is a considerable danger of 
malnutrition exacerbating the already difficult symptoms of CD. 
Attention has been drawn to the possible need for higher than 
normal levels of vitamins such as vitamin D or lipids such as 
long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (15, 
16). What has not always been recognized is the role of dietary 
components that are not currently included in essential lists. For 
example, prebiotics and probiotics may be important in regulat-
ing the gut microbiota, and their importance may be missed 
in some assessments (17–19). Phytochemicals are sometimes 
called “non-nutrients.” Although these are not included in lists of 
essential nutrients, many of them play key roles in maintaining 
genomic stability and in modulating the composition of the gut 
microbiome (7, 20, 21). These could be key factors in helping to 
prevent the development of CRC in IBD.
Irrespective of nutrient composition, it has repeatedly been 
observed that foods considered to be beneficial for some indi-
viduals may actually cause adverse effects in others (11, 22). 
Individuals with the diseases differ in genetic, epigenetic, and 
phenotypic characteristics, so it is not surprising that a single 
approach is unlikely to be beneficial to all. However, studies show-
ing the importance of genotype in the phenotypic characteristics 
of the diseases encourage the possibility of tailoring diets based 
on genetic and genomic information (23).
Genetic Basis of CD
Crohn’s disease was one of the subjects of early reports on genome-
wide association studies (GWAS). At that time, it appeared that 
there could be up to eight loci affecting disease susceptibility (24). 
Since that time, large international groupings have performed a 
meta-analysis of CD and UC GWAS scans, as part of activity of 
the International IBD Genetics Consortium (IIBDGC) (25). This 
was followed by extensive validation of significant findings, from 
data on a combined total of more than 75,000 cases and controls. 
These efforts initially revealed 163 distinct genetic loci affecting 
susceptibility to IBD overall (26), but this number has more 
recently been expanded to 201 (27). A number of these genes 
are involved in primary immune deficiencies, characterized 
by a dysfunctional immune system and increased susceptibil-
ity to serious infections. In particular, there is a considerable 
overlap between IBD loci and the immune-mediated disorders, 
ankylosing spondylitis and psoriasis (27). This study found 
considerable overlap between susceptibility loci for IBD and 
mycobacterial infection, which relationships were emphasized by 
further analyses using coexpression network analysis. Many of 
the identified loci contain genes involved in microbial handling, 
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and host–microbe interactions clearly play an important role in 
disease susceptibility (26).
In further analyses of these datasets, the IIBDGC detailed 
fine-mapping project, clarified the nature of these genes and 
their interactions, and suggested that phenotypically there should 
be three rather than just two main classes of IBD and that CD 
should be categorized into two distinct classes depending upon 
its location (27). Each of these classes of disease has characteristic 
genetic and phenotypic characteristics. The detailed nature of the 
genes and networks involved in disease susceptibility enables a 
rationale for predicting nutritional requirements that may not be 
evident through standard therapeutic approaches.
Possible Deviations from Conventional 
Nutrient Requirements in CD
There is a considerable scientific input into the setting of recom-
mended daily nutrient intakes. While these may be good for the 
general population, they may often not reflect the actual require-
ments for CD patients. Figure 1 illustrates the identification of 
specific dietary components or items that may be important for 
different groups of CD patients, according to their genotype and 
the nature of the gut microbiome. Genetic testing can indicate the 
primary single-nucleotide polymorphisms (SNPs) of importance 
M
Long chain n-3 PUFA 
and vitamin D
Epigallochatecin
gallate
Prebiotic mix
Genomic stability
Immune response
Microbial diversity
FiGURe 1 | effects of various identified dietary components on immune response, microbial diversity, and genomic stability, with use justified by 
genetic testing. The use of the immunochip supplemented with fine mapping enables very detailed understanding of the nature of the genes involved in CD 
susceptibility of an individual. A number of the affected genes play key roles in inflammatory response. If the majority of the affected genes favor inflammation, then a 
primary recommendation may be to enhance the intake of long-chain n-3 PUFA, especially EPA and DHA. Both of these play distinctive and major controlling roles 
in inflammatory response (16). If genes affecting microbial response and signaling pathways predominate, then probiotics may be an especially important dietary 
component (35). In addition, various prebiotics such as the food combination illustrated here act to stimulate the growth of beneficial gut microbes (14, 37). Both 
vitamin D and various phytochemicals, including the active component in green tea, EGCG, are recognized as having roles in each of these processes and are likely 
to be beneficial to CD patients at higher than standard dietary recommendations (15, 38–40). Maintenance of genomic stability will play an important role in slowing 
progression of CD or the development of CRC (7, 21). Thus, diets containing a good balance of such components, possibly tailored according to genotype, may act 
to complement or slow the need for recognized therapeutics in CD. Images from Can stock photos.
at an individual level. If, for example, some of the interleukin (IL) 
genes are affected, these are primarily involved in inflammation 
(28, 29), although they may have a downstream effect on the 
microbiota. Thus, supplementation with long-chain n-3 PUFA 
or fish oils may be a nutritional approach to prioritize (30–32). 
Similarly, identification of NOD2 or ATG16L1 gene variants 
indicate that ability to respond appropriately to colonic bacteria 
is compromised (33, 34), and prebiotics and/or probiotics may 
provide an important starting point (14, 35–37). For all these 
individuals, especially those carrying a number of variant SNPs, 
it becomes important to protect against genomic instability since 
this will reflect a propensity for cancer development. In this 
respect, certain nutrients, especially vitamin D and phytochemi-
cals, may play an important role (7).
While it is desirable to have studies in CD patients, in practice 
much of this work comes from mouse models, developed to 
reflect our understanding of the genetics of CD (41–44). Two of 
these models will be described here.
The IL-10 gene-deficient (IL-10−/−) mouse model lacks a 
functional version of the anti-inflammatory cytokine, IL-10. 
IL-10−/− mice, inoculated with normal intestinal bacteria, have 
been used to investigate the role of various dietary components 
in intestinal inflammation, including mechanistic studies that 
consider transcriptomic, metabolomic, and proteomic effects 
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(41, 45, 46). The multidrug-resistant (mdr1a−/−) mouse model 
carries a deletion mutation enabling disease-causing micro-
organisms (bacteria, viruses, fungi, or parasites) to resist a 
range of important drugs (antibiotics, antifungal, antiviral, and 
antiparasitic drugs) targeted at eradicating the organism (47). 
Mdr1a knockout mice are susceptible to developing a severe 
spontaneous intestinal inflammation in pathogen-free animal 
facilities.
Micronutrients
Fenech has reviewed the role of various micronutrients in slow-
ing the progress of genomic instability, a key component in the 
progression of digestive diseases and the initiation of cancer (8, 
48, 49). He points to the importance of individualizing dietary 
components according to genotype and shows increased dietary 
intake of vitamin E, calcium, folate, retinol, and nicotinic acid 
being associated with less DNA damage and a need to define 
the optimal amount being especially important for riboflavin, 
pantothenic acid, and biotin. These three have been distinguished 
because of increased DNA damage being especially evident at 
higher doses. Fenech has described high-throughput nutrient 
arrays that enable defining, on an individual basis, the optimal 
combination of nutrients for DNA damage prevention, mainte-
nance of telomere integrity (important in cancer risk), and cancer 
growth control (48).
We have more generally reviewed vitamin and mineral require-
ments to maintain genomic stability, especially in the context of 
the micronutrient genomics project (50). It is noteworthy that 
certain of these nutrients may be required in higher than usual 
amounts in CD, since they are utilized in the control of immune 
response and inflammation. Our own studies have particularly 
emphasized the importance of getting not only the correct form 
of selenium but also the appropriate level according to genotype 
(51, 52).
Vitamin D is an important vitamin that appears to be required 
at higher than anticipated levels in CD patients (15). This may 
partly be caused by genetic requirements, and it is of interest that 
a number of SNPs associated with vitamin D uptake and distribu-
tion actually appear on the immunochip, used in the important 
study of IBD risk genes by Jostins and coworkers (26). Again, 
there is a specific link with inflammatory processes and with con-
trol of microbiota in the identified genes. Higher plasma vitamin 
D levels have been associated with a reduced risk of Clostridium 
difficile (53), whereas reduced levels of circulating vitamin D 
enhance the risk of cancer and other inflammatory diseases (54, 
55). We suggest that such an observation may add fuel to an 
argument that higher than current recommended daily intakes 
of vitamin D may be particularly appropriate to CD patients.
Dietary Lipids
Many naturally occurring agents directly bind with and activate 
peroxisome proliferator-activated receptor gamma (PPAR-γ 
or PPAR gamma), a type II nuclear receptor that in humans is 
encoded by the PPAR-γ gene. Agents binding this include various 
PUFAs including arachidonic acid and arachidonic acid metabo-
lites. PPAR-g regulates fatty acid storage and glucose metabo-
lism. The genes activated by PPAR-g stimulate lipid uptake by 
adipocytes and play an important role in regulating inflammation 
and cancer cell growth (46).
Peyrin-Biroulet and coworkers (56) demonstrated antimicro-
bial functions of the PPAR-γ gene products in maintaining epi-
thelial expression of a type of colonic beta-defensin (mDefB10 in 
mice, DEFB1 in humans). In mutant mice carrying this mutation, 
these authors showed defective killing of a number of bacteria 
including Candida albicans, Bacteroides fragilis, Enterococcus 
faecalis, and Escherichia coli. It appears that colonic involvement 
in CD is linked to reduced expression of DEFB1, independent of 
inflammation. Thus, it has been suggested that PPAR-g-targeting 
by either drugs or nutrients could prevent colonic inflammation 
by restoring antimicrobial immunity in CD.
There have been variable results across various studies in 
relation to the association of common PPAR-g variants (C161T 
and Pro12Ala) with IBD. While Hume and coworkers reported 
no association in an Australian cohort (57), Shrestha et al. found 
suggestive relationships in Chinese but not Dutch patients (58). 
However, the Pro12Ala variants appeared to be protective against 
the development of CD in European Caucasians (57). Such stud-
ies have led support to the suggestion that there are significant 
ethnic differences in the phenotypic expression of this variant. 
There is reason to believe that diet, including lipids, may play a 
key role in this effect.
Conjugated linoleic acid has been shown to modulate immune 
responses in patients with mild to moderately active CD (59), 
and there is some support for this being through modulation of 
PPAR-g. In their Caucasian CD cohort, Ferreira and coworkers 
(60) found that a high intake of total, saturated, and monounsatu-
rated fats and a higher ratio of n-6/n-3 PUFAs were associated 
with a more active phenotype. They studied the effects of four 
genetic polymorphisms, including the two PPAR-g SNPs 161C/T 
and Pro12Ala SNPs, in a case–control population. Although they 
reported no significant effects of these SNPs on disease suscepti-
bility per se, they found that the presence of either of these SNPs 
led to a more detrimental effect of a high intake of total and trans 
fats.
The effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) 
are also modified by genotype, especially the nitric oxide synthase 
(NOS3) gene (61). These authors reported associations of plasma 
fatty acid composition and NOS3 SNP genotypes (rs11771443, 
rs1800783, rs1800779, rs1799983, rs3918227, and rs743507) in 
450 individuals with the MetS from the LIPGENE dietary inter-
vention cohort. They found that several markers of inflammation 
were significantly different between the genotype groups. There 
was a significant gene–nutrient interaction between the NOS3 
rs1799983 SNP and plasma n-3 PUFA status on plasma triacyl-
glycerol (TAG) concentrations. Minor allele carriers (AC + AA) 
were considerably more responsive to changes in plasma n-3 
PUFA than major allele homozygotes. Such individuals are likely 
to benefit even more from long-chain n-3 PUFA consumption 
than the general population in order to reduce inflammation in 
CD (16).
Phytochemicals
Polyphenols are secondary metabolites of higher plants and one 
of the largest groups of natural products. Although not usually 
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considered in the same class as essential nutrients, various poly-
phenols could play an important role in CD susceptibility and 
progression. A range of polyphenols have been shown to modulate 
inflammation, especially in genetically deficient mouse models. 
For example, a green tea extract enriched in polyphenols was able 
to modulate colonic inflammation in mice lacking the multid-
rug resistance gene (Mdr1a−/−). Mice were fed control or green 
tea-enriched diets for 21–24 weeks of age, after which a colonic 
histological injury score was obtained, colonic gene expression 
analyzed using microarrays, and colon protein expression also 
measured (20). The authors reported reduced abundance of tran-
scripts and proteins associated with immune and inflammatory 
response, which suggested that its anti-inflammatory activity is 
mediated by multiple molecular pathways.
Cruciferous vegetables, such as cabbage and broccoli, contain 
two types of sulfur-containing phytochemicals – glucosinolates 
and S-methyl cysteine sulfoxide. While these chemicals have a 
range of effects generally considered to be beneficial in the popu-
lation at large, this group of food plants also polarizes individuals 
with CD. Laing and coworkers associated SNPs and the beneficial 
or adverse effects of the 10 most commonly eaten foods in this 
group (22). One of the SNPs that showed exceptionally beneficial 
properties to individuals consuming cruciferous vegetables was 
in the defensin (DEFA6) gene. Conversely, one SNP strongly 
associated with adverse effects was in the major histocompat-
ibility complex, which characterizes one important group of CD 
patients (27).
The main polyphenol in green tea is (−)-epigallocatechin gal-
late (EGCG). Unno and coworkers showed this compound at levels 
of 0.6% to have strong effects on gut microbiota and biomarkers 
of colonic fermentation in rats (38). They found a significant 
reduction of Clostridium spp and an increased gut occupation by 
Bacteroides. Smaller changes were seen for Bifidobacterium and 
Prevotella. ECGC also has effects on genomic stability, suggesting 
that it could be protective against cancer development in IBD 
(7, 21).
Ellagic acid and ellagitannins are a class of hydrolyzable tan-
nins found in some fruits and nuts. At least in in vitro studies, 
there is good evidence that these may have the potential to reduce 
inflammation in genetically modified cells (62). Boysenberries, 
a hybrid Rubus berry, are among the best food sources of ella-
gitannins, although chestnuts and pomegranates also have high 
concentrations. Nasef and coworkers found effects modulated 
through toll-like receptors 2 and 4 of extracts from blackcurrants 
and feijoa, which may have been associated with elligitannins 
(63). The significance of these results awaits confirmation by 
in vivo testing.
Resveratrol is another polyphenol that has been shown to 
protect against genomic instability. It acts as an antioxidant pro-
tecting against free radical-induced DNA damage and is likely 
to play a protective role in gut inflammation and progression to 
CRC (64).
Probiotics and Prebiotics
The diversity of microbiota appears as a key characteristic that 
may predict response to therapy in CD (65). In addition, it has 
been suggested that a discriminant score of intestinal microbiota 
may provide an index of disease activity in CD (66). While fecal 
transplants have received some recognition as therapy for CD 
generally, these are not sustainable over a long period (67). 
Additionally, a number of concerns have been raised about their 
true efficacy (68). Regulating the gut microbiota through diet may 
provide a more sustainable solution. There is no question but that 
diet plays a major role in modulating the colonic microbiota (69). 
Certain nutrients, especially vitamin D, may play an important 
role in this respect (70).
Probiotics have been defined by FAO/WHO as “live micro-
organisms that confer a health benefit to the host when admin-
istered in adequate amounts.” Especially in combination with 
prebiotics (plant substrates that enable modulation of colonic 
microbiota), these may be especially beneficial to CD patients (35, 
71). Probiotic bacteria have been shown to produce conjugated 
linoleic acid in the gut, which in turn plays a role in suppress-
ing disease symptoms through targeting PPAR-γ gamma (42). 
Prebiotics are digested and fermented to form short-chain fatty 
acids, which themselves enhance the growth of certain important 
colonic bacteria (17).
Additionally, an increasing number of plant polyphenols are 
being identified to have effects on colonic microbiota identifica-
tion and regulation (64). Innovative prebiotic/probiotic foods 
are also being developed and may have promise in a clinical 
context (71).
Methylation, miRNAs, and CD
Not only genetics per  se but also certain epigenetic events are 
associated with susceptibility to CD, disease progression, and 
CRC development.
DNA methylation has been considered for its role in the 
development of CD. Whole-blood DNA methylation profiles 
were compared in treatment-naive children with CD and 
healthy controls, as measured using the Illumina 450  K 
platform (72). Sixty-five differentially methylated CpG sites 
were identified as reaching epigenome-wide significance. 
The most significantly differentially methylated region in 
patients with CD involves the transcription start site for 
microRNA (miR)-21.
microRNAs (miRNAs) are recognized as playing an essential 
role in the development and control of the innate and adaptive 
immune system. These are small non-coding RNA molecules that 
lead to post-translational gene silencing and control gene expres-
sion in diverse biological processes, including inflammation. 
miRNA genes occur within intronic sequences of protein-coding 
genes, within intronic or exonic regions of non-coding RNAs, 
are intergenic (72). As well as miR-21, various other miRNAs 
including miR-192, miR-122, miR-29, and miR-146a may be 
implicated in CD. Krissansen and coworkers found that increased 
circulating levels of miR-595 and miR-1246 related to a highly 
aggressive form of the disease (73). Because miRNAs play a major 
role in regulating gene expression, they are being looked at as 
therapeutic targets and also as biomarkers for aggressive disease 
development.
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effects of Selected Nutrient Classes on 
Gene expression in CD
There are no published reports of individual nutrients affecting 
gene expression in CD from human studies because the defini-
tive studies would be unethical to perform. However, there are 
a number of studies in animal models or tissue culture systems, 
which provide useful information.
Micronutrients
The active binding sites of 1,25-dihydroxyvitamin D3 (1,25D) 
are likely to regulate gene expression at the cellular level (74). 
This active form of vitamin D has been shown to interact with 
the epigenome through effects on DNA methylation, histone 
acetylation and miRNA, as well influencing pre-mRNA splicing. 
Genomic profiling has identified a set of 1,25D regulated genes 
that are especially relevant to cancer prevention. For example, 
Ma and coworkers compared 1,25D-regulated miRNA expres-
sion profiles in a human cancer cell line in comparison with a 
highly tumorigenic and metastatic variant, using miRNA qPCR 
panels (75). The two lines showed distinctly different miRNA 
expression profiles that the authors suggest are likely to influence 
the behavior of different tumor cells and are relevant to both the 
susceptibility to and subsequent behavior of cancer.
Human studies on vitamin D3 supplementation have enabled 
dissection of high from low responders in a pre-diabetic study 
population (76). Only around 60% of these subjects responded 
to supplementation. While VDR receptor gene polymorphisms 
played a role in this, other clinical parameters such as the level of 
parathyroid hormone were also important. The authors suggested 
that vitamin D3-induced changes in human peripheral blood 
mononuclear cells can be described by transcriptomics. Added 
to information from other serum biomarkers, these allow the 
identification of those subjects who will (or will not) respond to 
vitamin D supplementation.
Long-Chain Omega-3 PUFA
These compounds have sometimes been described as master 
regulators of gene expression (16). Serhan and coworkers have 
discussed the function of long-chain omega-3 PUFA as novel 
pro-resolving mediators in the resolution of acute inflammation. 
They have discovered a new genus of pro-resolving lipid media-
tors that is temporally produced by resolving exudates that enable 
a return to homeostasis. These not only have anti-inflammatory 
actions but also enhance microbial clearance. Such properties 
make the two long-chain omega-3 PUFAs, EPA and DHA, essen-
tial nutrients not only for protection against CD in the first place 
but also for reducing inflammation and thereby reducing disease 
progression.
Knoch and coworkers compared the effects of EPA sup-
plementation with that of oleic acid (OA) as control in the 
IL-10−/− mouse model (77). They found that EPA reversed the 
decrease in colon fatty acid beta-oxidation gene expression 
observed in OA-fed mice. The mice fed with the OA diet showed 
a decrease in the expression of antioxidant enzyme genes, 
as well as those involved in detoxification, when compared 
with wild-type (C57Bl) mice on the same diet. In contrast, 
EPA up-regulated the expression of these same enzymes. The 
authors suggested that these results imply that EPA might 
have a potential anti-inflammatory effect on colon tissue. 
In support of this hypothesis was the observation that EPA 
also activated expression of the PPAR-α gene, which regulates 
the expression of proinflammatory and immunomodulatory 
genes.
Phytochemicals
Cytochrome P450s (CYPs) play an essential role in the metabolism 
of endogenous and exogenous molecules (78). They facilitate the 
biosynthesis of a number of essential molecules, including fatty 
acids, lipid-soluble vitamins, and steroid hormones. They also 
metabolize most pharmaceuticals as well as carcinogenic com-
pounds. CYP gene expression is regulated by a number of poly-
phenols, such as EGCG. This molecule not only has antioxidant 
properties but can be pro-oxidant at very high levels, although 
generally beneficial in modulating the risk and progression of 
inflammatory diseases and cancer (79). The review by Korobkova 
extensively summarizes the effects of a range of polyphenols on 
CYP metabolism, with flow-on implications for gene expression 
(79). Aylissi and coworkers have also summarized the epigenetic 
effects of natural polyphenols, which have implications for the 
modulation of gene expression (80).
An extract of green tea, enriched in polyphenols (GrTP), was 
tested for effects on colonic inflammation in the MDRa−/− mouse 
model utilizing a transcriptomics approach (20). The histological 
injury score was significantly lower in the GrTP-fed mice than in 
the control group. Colon mRNA transcripts were assessed using 
microarrays. They revealed a reduced abundance of transcripts 
associated with immune and inflammatory response and an 
abundance of those associated with xenobiotic metabolism 
pathways, suggesting an anti-inflammatory effect mediated by 
diverse mechanisms. PPAR-a and signal activator of transcription 
1 (STAT1) appear as two key regulatory molecules in these events.
Curcumin has been studied for effects on gene expression, 
using the N2A cell line (81). Treatment with this polyphenol leads 
to suppression of NF-kappaB and its downstream proinflamma-
tory targets including COX-2 and iNOS. Resveratrol has also 
been shown to alter gene expression patterns in another cancer 
cell line (82). Microarray analysis showed effects on apoptosis-
related genes. The green tea polyphenol, EGCG, has been used as 
an exemplar of a polyphenol showing effects on gene expression 
revealing other than antioxidant properties (39). In particular, 
EGCG regulates signal transduction pathways, transcription fac-
tors, DNA methylation, mitochondrial function, and autophagy, 
several of which effects are relevant to CD patients. ECGC has 
also been shown to attenuate the activation of STAT3, which 
again is an important pathway in CD (83). In an overview on the 
effects of polyphenols on gene expression, Joven and coworkers 
suggest that these provide an excellent illustration as to how we 
may be able to eat our way out of chronic diseases (84).
Dietary curcumin and rutin were compared for effects on 
colonic inflammation and gene expression in the MDR1−/− 
mouse model (44). Curcumin but not rutin significantly reduced 
the histological evidence of inflammation in this mouse model. 
Microarray and pathway analysis implied that the mechanism was 
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likely through up-regulation of xenobiotic metabolizing enzyme 
expression and a down-regulation of proinflammatory pathways.
Probiotics and Prebiotics
Plaza-Diaz and coworkers found evidence that a range of probiot-
ics modulate the expression of immunity and inflammatory genes 
in the gut, which appear especially relevant to CD. They performed 
a systematic review to conclude that strains of Bifidobacterium, 
Lactobacillus, Escherichia coli, Propionibacterium, Bacillus, and 
Saccharomyces influence the gene expression of mucins, Toll-like 
receptors, caspases, NF-κB, and ILs, leading to an anti-inflamma-
tory response in cultured enterocytes. Similar results were found 
in animal models ranging from fish to mice, rats, and piglets (85).
Prebiotics can also modulate host gene expression, with 
potentially beneficial flow-on effects relevant to CD (86). Sauer 
and coworkers studied the effects of products formed from an 
inulin derivative incubated with human gut flora (87). They con-
sidered the expression of 96 genes related to biotransformation 
using cDNA microarrays. The pattern of gene expression sug-
gested various effects likely to protect the cells from carcinogenic 
compounds. Zenholm et al. used a Caco-2 gastrointestinal cancer 
cell model to study the effects of an oligosaccharide and a fructo-
oligosaccharide in reducing the expression of IL-12p45, IL-8, and 
TNF-α (88).
Human Studies on the Benefits of this 
Combination of Nutrients on Gene 
expression
Marlow and coworkers reported on gene expression effects of a 
specific diet containing examples of the nutrient classes under dis-
cussion (89). They developed a Mediterranean-inspired diet whose 
ingredients were delivered to participants each week over a 6-week 
intervention period along with recipes and tips for maintaining a 
healthy diet, and participants were also contacted for encourage-
ment on a regular basis. The diet did not contain the amounts of 
whole grains and diary products common in the Mediterranean 
but had a seasonal range of fruits and vegetables (various vitamins 
and polyphenols), two meals of oily fish per week (omega-3 and 
vitamin D), green tea (EGCG), and probiotic capsules. Marlow 
and coworkers considered the effects on symptoms, biomarkers of 
inflammation, and the gut microbiota as well as classic measures 
of inflammation such as C-reactive protein (CRP), and they also 
used a transcriptomic end point. They found that adherence to 
the diet for 6 weeks reduced the established biomarkers of inflam-
mation. However, transcriptomic analysis provided an important 
biomarker, showing that the expression of certain genes important 
in the etiology of CD was beneficially modulated. The diet also 
resulted in a trend of normalizing the microbiota.
Systems Biology Approaches to validate 
the efficacy of Dietary Approaches to 
Disease Control
In previous sections, we have identified a number of nutri-
ents that are especially important for CD development and 
progression. Other nutrients will undoubtedly play an additive 
role. Systems biology links the interactions among genes, gene 
products, and environmental factors. As Polytarchou et al. have 
suggested, there is reason to suggest that this is ready for prime 
time in CD research (90). It is being increasingly used to refine 
desirable nutrition for an individual and treat complex human 
diseases, such as CD. Figure 2 illustrates the way in which these 
technologies have the potential to revolutionize conventional 
CD diagnosis and treatment by providing a strong scientific 
basis for nutritional therapy. As indicated in previous sections 
and Figure  1, genetic screening will inform the desirability of 
certain foods or nutrients that will become part of the regular 
diet (26, 27). The benefit of such a combination of foods may 
be tested, at an individuals or group level, using transcriptomic 
approaches (89), while the long-term benefits in protection 
against disease progression may be interrogated using proteomic 
and/or metabolomic approaches (91, 92). Changes in the gut 
microbiota will also be important (93).
Fiocchi has identified four components of IBD pathogenesis 
as environment, genetics, gut microbiota, and mucosal immune 
response, which can be defined by the terms “expososome,” 
“genome,” “microbiome,” and “immunome” (94). None of these 
act independently, but interact (the “interactome”), resulting 
in the emergence of IBD. Polytarchou and coworkers (90) have 
stressed the way in which novel computational methodologies can 
now integrate high-throughput molecular data. They suggest that 
a systems biology approach could identify the central regulators 
in the IBD interactome. This work suggests that identification of 
key nutrients and their interactions with these central networks, 
possibly at an individual level, might lead to novel therapeutic 
approaches to CD.
Metabolomic approaches may provide important tools for 
understanding the differences between individuals in response 
to dietary components. For example, Lin and coworkers used 
a mouse model to investigate the effects of feeding kiwifruit-
derived extracts from two different species (96). Not only did 
they find differences in anti-inflammatory activity between 
the green (Actinidia deliciosa) and gold-fleshed (Actinidia 
chinensis) kiwifruit extracts, but the efficacy of these extracts 
was modulated by the variant IL-10 genotype. This same mouse 
model and experimental approach revealed gradual changes in 
the metabolome as disease developed, particularly decreased 
levels of very low-density lipoprotein and increased low-density 
and very low-density lipoproteins and various PUFAs (97). The 
metabolome also interrelates with the microbiome, suggesting 
the possibility of utilizing targeted metabolomics for monitoring 
the consequences of therapeutically manipulating the microbial 
community as adjunct therapy in CD (98).
Much of the proof of concept of beneficial effects of certain 
diets in CD patients has been based on animal or tissue culture 
studies, rather than humans, since there are obvious ethical 
constraints in working with people. The classic biomarker of 
inflammation is considered to be CRP, while fecal calprotectin 
has gained considerable ground. However, as illustrated in the 
study by Marlow and coworkers, transcriptomics provides a more 
sensitive and more informative biomarker of beneficial effects of 
a selected diet in CD than CRP (89).
Genetics-enabled food selection
Transcriptomics-validated diet
Biomarkers of 
human response
Biomarkers of
microbial response
Metabolomics Proteomics Metabonomics
FiGURe 2 | Flowchart showing how genetic and genomic technologies may inform optimal nutritional modulation of CD. Genetic characterization of 
human DNA and the nature of the associated gut microbiome enable selection of an individualized diet for CD patients. While long-chain omega-3 PUFA containing 
fish or dietary supplements may be appropriate for most individuals, the exact nature of the most desirable fruits, vegetables, and supplements will vary. Although 
we are now in a position to make informed guesses, the proof of efficacy of the dietary choice would and probably should be informed by genomic approaches. In 
particular, there is reason to believe that the inflammation associated with CD will itself consume the various nutrients at higher than average levels. These 
techniques are now sufficiently sensitive to allow testing the effect of the selected dietary strategy following short-term intervention studies. Blood, urine, and feces 
samples would be required, before and after the study period. Changes in gene expression as monitored by transcriptomic profiles from peripheral blood 
mononuclear cells show which CD-related genes have modulated activity (89). Urine or fecal samples can be used for metabolomic and proteomic techniques (91, 
94). These may be utilized to monitor dietary compliance and also to provide biomarkers relevant to CD progression. The microbiota profile can be estimated from 
stool samples, and modulation of microbiota will provide important complementary information on whether the dietary selection has the desired effect on slowing 
disease progression (67, 89, 95). Images from Adobe stockimages and from Ref. (89).
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Research into gastrointestinal cancer has highlighted the 
importance of biomarkers, especially miRNAs, usually taken 
from colonic endoscopies. There is considerable interest in the 
discovery that miRNAs are present in serum in a cell-free state, 
highlighting the possibility of their potential use as non-invasive 
biomarkers (99). At this time, extracellular miRNAs have been 
identified in most biological fluids, including serum, urine, saliva, 
and breast milk. They are being considered as novel biomarkers, 
with considerable potential for predicting disease course and 
response to therapy.
Metabolites reflect the physiological phenotype, providing a 
molecular readout of the cell status (95). Such measures, taken 
from various biological fluids, can lead to the identification of 
“marker metabolites” that differentiate health from disease. 
In particular, metabonomics (spectroscopy-based metabolic 
profiling) of fecal extracts has been used to differentiate active 
from inactive CD. This method comes across as a powerful 
non-invasive diagnostic tool able to characterize changes in the 
metabolic profile associated with malabsorption and dysbiosis 
(100). Specific metabolites that distinguished groups with active 
from those with inactive disease included N-acetylated com-
pounds and phenylalanine, low-density lipoproteins, and very 
low-density lipoproteins (101). More generally, metabolomics is 
being used in human studies to monitor compliance with required 
dietary changes and also efficacy of the change in slowing disease 
progression (102).
Proteomics is defined as the large-scale study of proteins, 
particularly their structures and functions (103). This technique 
has been used to validate conclusions from other technologies 
in a series of mouse studies by Barnett and coworkers (20, 46, 
104). In studies on green tea polyphenols, proteomic analysis 
supported the conclusions from microarrays regarding the 
mechanism of action of the polyphenol-enriched extract (20). 
Application of the same technology to studies of n-3 and n-6 
PUFAs (arachidonic acid and EPA) showed that the proteomic 
analysis identified some actions that had not been apparent from 
transcriptomic studies (46). These authors emphasized the com-
plementary nature of these two approaches and the importance 
of using the two in concert to better understand the nature of 
complex diseases such as CD.
The accurate diagnosis of CD has often lagged behind disease 
presentation. Proteomics is being increasingly used for early and 
accurate diagnosis of CD as well as for monitoring the course of 
the disease (92). By providing information on the nature of the 
disease process, such technology may inform appropriate treat-
ment regimes. Although intestinal tissue will provide the most 
information, blood, urine, and stool are increasingly providing 
highly predictive substitutes that are considerably less invasive 
than the requirement for a colonoscopy.
The toolbox for studying microbiota has become more power-
ful in recent years, with metagenomics reflecting the study of 
DNA, metatranscriptomics the total transcribed RNA, and 
metaproteomics the protein associated with the microbiota. 
Draft genome sequences have been derived for more than 1,000 
human-associated microorganisms derived from the gastroin-
testinal tract of more than 100 humans (70). Bioinformatics pro-
vides an essential tool to tie together these multi-omic analyses 
of IBD (105).
Conclusion
There is a great deal written about desirable intakes for various 
classes of food and nutrients. However, the genetic background of 
CD would appear to make certain nutrients more important than for 
the general population, albeit differing somewhat according to the 
genetics of the individual patient. Such nutrients will be especially 
important during a flare-up of the disease, but will also be crucial in 
slowing disease progression. Proof of principle of these assertions 
has been largely dependent on tissue culture or animal models to 
date. However, improvements in sensitivity of various technologies, 
especially transcriptomics, proteomics, and metabolomics, enable 
non-invasive sampling of humans from blood, urine, and/or stool 
samples, after relatively short-term human intervention studies. We 
suggest that there is justification for a paradigm shift in diagnostic 
tools and nutritional therapy for CD, involving a systems biology 
approach for implementation (106).
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